Display options
Cite
Franceschi S, Mazzanti CM, Lessi F, et al. Investigating molecular alterations to profile short- and long-term recurrence-free survival in patients with primary glioblastoma. Oncol Lett. 2015;10(6):3599-3606doi: 10.3892/ol.2015.3738.
Franceschi, S., Mazzanti, C. M., Lessi, F., Aretini, P., Carbone, F. G., LA Ferla, M., Scatena, C., Ortenzi, V., Vannozzi, R., Fanelli, G., Pasqualetti, F., Bevilacqua, G., Zavaglia, K., & Naccarato, A. G. (2015). Investigating molecular alterations to profile short- and long-term recurrence-free survival in patients with primary glioblastoma. Oncology letters, 10(6), 3599-3606. https://doi.org/10.3892/ol.2015.3738
Franceschi, Sara, et al. "Investigating molecular alterations to profile short- and long-term recurrence-free survival in patients with primary glioblastoma." Oncology letters vol. 10,6 (2015): 3599-3606. doi: https://doi.org/10.3892/ol.2015.3738
Franceschi S, Mazzanti CM, Lessi F, Aretini P, Carbone FG, LA Ferla M, Scatena C, Ortenzi V, Vannozzi R, Fanelli G, Pasqualetti F, Bevilacqua G, Zavaglia K, Naccarato AG. Investigating molecular alterations to profile short- and long-term recurrence-free survival in patients with primary glioblastoma. Oncol Lett. 2015 Dec;10(6):3599-3606. doi: 10.3892/ol.2015.3738. Epub 2015 Sep 23. PMID: 26788176; PMCID: PMC4665722.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2015 Dec;10(6):3599-3606. doi: 10.3892/ol.2015.3738. Epub 2015 Sep 23.

Investigating molecular alterations to profile short- and long-term recurrence-free survival in patients with primary glioblastoma.

Oncology letters

Sara Franceschi, Chiara M Mazzanti, Francesca Lessi, Paolo Aretini, Francesco G Carbone, Marco LA Ferla, Cristian Scatena, Valerio Ortenzi, Riccardo Vannozzi, Giovanni Fanelli, Francesco Pasqualetti, Generoso Bevilacqua, Katia Zavaglia, Antonio G Naccarato

Affiliations

  1. Department of Translational Research and of New Surgical and Medical Technologies, University Hospital of Pisa, Pisa I-56126, Italy; Genomic Section, Pisa Science Foundation, Pisa I-56121, Italy.
  2. Genomic Section, Pisa Science Foundation, Pisa I-56121, Italy.
  3. Department of Translational Research and of New Surgical and Medical Technologies, University Hospital of Pisa, Pisa I-56126, Italy.
  4. Department of Neurosurgery, University Hospital of Pisa, Pisa I-56124, Italy.
  5. Radiotherapy Unit, University Hospital of Pisa, Pisa I-56126, Italy.

PMID: 26788176 PMCID: PMC4665722 DOI: 10.3892/ol.2015.3738

Abstract

Glioblastoma (GB) is the most aggressive type of primary brain tumor. Despite the progress in recent years regarding the diagnosis and treatment of GB, the recurrence rate remains high, due to the infiltrative and dispersive nature of the tumor, which typically results in poor patient prognosis. In the present study, 19 formalin-fixed, paraffin-embedded GB samples were selected from patients with GB tumors. The samples were classified into a short or long recurrence-free survival (RFS) group, based on the time of first recurrence of the disease in the patients. The 19 samples were molecularly characterized for mutations in the isocitrate dehydrogenase 1 (IDH1) gene, amplification of the epidermal growth factor receptor (EGFR) gene, presence of the EGFR variant III, and methylation of the promoter region of the O

Keywords: gene expression; glioblastoma; molecular alterations; outcome prediction; recurrence

References

  1. Neurosurg Focus. 2006 Apr 15;20(4):E5 - PubMed
  2. Cancer Res. 2004 Sep 15;64(18):6503-10 - PubMed
  3. Tumour Biol. 2013 Aug;34(4):1969-78 - PubMed
  4. Neoplasia. 1999 Aug;1(3):208-19 - PubMed
  5. Clin Cancer Res. 2010 Apr 15;16(8):2443-9 - PubMed
  6. PLoS One. 2014 Jan 13;9(1):e85102 - PubMed
  7. Cancer Cell. 2006 Mar;9(3):157-73 - PubMed
  8. Cell Adh Migr. 2009 Oct-Dec;3(4):334-6 - PubMed
  9. Int J Cancer. 1998 Mar 16;75(6):864-72 - PubMed
  10. Acta Neuropathol. 2007 Aug;114(2):97-109 - PubMed
  11. BMC Med Genomics. 2014 Jun 02;7:30 - PubMed
  12. Clin Cancer Res. 2013 Feb 15;19(4):764-72 - PubMed
  13. J Clin Oncol. 1999 Aug;17(8):2572-8 - PubMed
  14. Neuro Oncol. 2008 Apr;10(2):162-70 - PubMed
  15. Blood Cancer J. 2013 Oct 11;3:e152 - PubMed
  16. PLoS One. 2013 Dec 02;8(12):e80707 - PubMed
  17. PLoS One. 2012;7(10):e47270 - PubMed
  18. Cancer. 2013 Feb 15;119(4):814-24 - PubMed
  19. N Engl J Med. 2005 Mar 10;352(10 ):987-96 - PubMed
  20. Cell. 2001 Dec 28;107(7):823-6 - PubMed

Publication Types